Rifampin — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	5-10 mg/kg	q12-24h	Duration: Weeks to months depending on infection Notes: For mycobacterial infections, use in combination with other antibiotics. For brucellosis, combine with doxycycline (5 mg/kg q12h) for 4-6 weeks.
Cat	PO	5-10 mg/kg	q12-24h	Duration: Weeks to months Notes: Use in combination with other antibiotics for mycobacterial infections. Monitor for hepatotoxicity.
Horse (foal)	PO	5-10 mg/kg	q12h	Duration: 4-8 weeks Notes: For Rhodococcus equi pneumonia, combine with a macrolide (e.g., clarithromycin or azithromycin).
Cattle	PO	10-20 mg/kg	q24h	Duration: Variable Notes: Not approved in many countries; use extra-label with caution. Withdrawal times must be observed.
Small Ruminants	PO	10-20 mg/kg	q24h	Duration: Variable Notes: Limited data; use extra-label with caution.
Rabbit	PO	10-20 mg/kg	q12-24h	Duration: Variable Notes: May cause gastrointestinal upset; use with probiotics.
Bird/Poultry	PO	10-15 mg/kg	q12-24h	Duration: Variable Notes: For avian tuberculosis, use in combination with other antimycobacterials.
Exotic/Other	PO	10-20 mg/kg	q12-24h	Duration: Variable Notes: Dose based on limited data; adjust based on species and response.

Clinical Indications & Species Uses

General Indications

Treatment of tuberculosis and other mycobacterial infections
Treatment of brucellosis (in combination)
Treatment of staphylococcal infections (in combination)
Treatment of Rhodococcus equi infections in foals

Dog (Canine)

Treatment of mycobacterial infections (e.g., tuberculosis, leprosy)
Treatment of brucellosis (in combination with doxycycline)
Treatment of methicillin-resistant staphylococcal infections (in combination with other antibiotics)
Treatment of chronic bacterial infections (e.g., osteomyelitis, prostatitis) when used in combination

Cat (Feline)

Treatment of mycobacterial infections (e.g., feline leprosy, tuberculosis)
Treatment of atypical mycobacterial infections
Treatment of methicillin-resistant staphylococcal infections (in combination)

Horse (Equine)

Treatment of Rhodococcus equi pneumonia in foals (in combination with macrolides)
Treatment of mycobacterial infections
Treatment of chronic bacterial infections

Cattle (Bovine)

Treatment of mycobacterial infections (e.g., Johne's disease - experimental)
Treatment of tuberculosis (in some countries, with regulatory approval)

Small Ruminants (Sheep / Goat)

Treatment of mycobacterial infections (e.g., caseous lymphadenitis - experimental)
Treatment of tuberculosis (with regulatory approval)

Rabbit & Small Mammals

Treatment of mycobacterial infections
Treatment of pasteurellosis (in combination with other antibiotics)

Avian & Poultry

Treatment of mycobacterial infections (e.g., avian tuberculosis)
Treatment of chlamydiosis (in combination with doxycycline)

Exotic & Other Species

Treatment of mycobacterial infections in reptiles, small mammals, and exotic pets
Treatment of mycobacteriosis in fish (experimental)

Pharmacology & Mechanism of Action

Drug Class: Antibiotic | Pharmacological Group: Rifamycin antibiotic

Mechanism of Action: Rifampin inhibits bacterial DNA-dependent RNA polymerase by binding to the beta subunit, thereby blocking RNA synthesis. It is bactericidal against susceptible organisms, including mycobacteria and some Gram-positive bacteria. It acts on both intracellular and extracellular bacteria.

Pharmacodynamics: Rifampin is a broad-spectrum antibiotic with activity against mycobacteria (e.g., Mycobacterium tuberculosis, M. bovis, M. avium complex), Staphylococcus spp. (including methicillin-resistant strains), and some Gram-negative bacteria. It is particularly effective against slow-growing organisms. Resistance develops rapidly when used as monotherapy due to single-point mutations in the rpoB gene.

⚡ Pharmacokinetics Summary

Absorption: Rifampin is well absorbed after oral administration, with peak plasma concentrations occurring 2-4 hours after dosing. Absorption is reduced when taken with food, but the clinical significance is variable.

Distribution: Widely distributed throughout the body, including into cerebrospinal fluid (especially with inflamed meninges), bone, and abscesses. It penetrates well into cells and achieves high concentrations in macrophages. Protein binding is approximately 80-90%.

Metabolism: Extensively metabolized in the liver to active and inactive metabolites. The drug induces its own metabolism via hepatic cytochrome P450 enzymes, leading to increased clearance with repeated dosing.

Excretion: Primarily excreted in bile and feces; a small amount is excreted in urine. Enterohepatic recirculation occurs. In renal impairment, dose adjustment is usually not necessary.

Half-Life: Dogs: 8-12 hours; Cats: 6-8 hours; Horses: 6-10 hours; Cattle: 4-8 hours; Humans: 3-5 hours (initial), decreases to 2-3 hours with repeated dosing.

Bioavailability: Oral bioavailability is approximately 90-95% in most species when given on an empty stomach.

Protein Binding: Approximately 80-90% (species-dependent)

Available Formulations & Strengths

Oral Capsule 150 mg, 300 mg (PO)

Oral Tablet 150 mg, 300 mg, 600 mg (PO)

Oral Suspension (pediatric) 10 mg/mL (as rifampin for oral suspension) (PO)

Injectable Solution (for IV infusion) 600 mg/vial (for reconstitution) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to rifampin or any rifamycin derivative
Concurrent use with protease inhibitors (e.g., for HIV) due to significant drug interactions
Severe hepatic impairment
Porphyria (may exacerbate)
Use in animals with known gastrointestinal obstruction or severe malabsorption

Warnings & Clinical Precautions:

Use with caution in animals with hepatic disease; monitor liver enzymes.
May cause reddish-orange discoloration of urine, feces, saliva, tears, and other body fluids; inform owners.
Induces hepatic microsomal enzymes; may reduce efficacy of concurrently administered drugs metabolized by CYP450.
Resistance develops rapidly if used as monotherapy; always use in combination for mycobacterial infections.
Use with caution in pregnant animals; safety not established.
In food animals, observe withdrawal times; extra-label use requires veterinary oversight.
May cause gastrointestinal upset; administer with food if vomiting occurs, but note reduced absorption.
In horses, may cause depression and anorexia at high doses.

Adverse Effects & Reactions

Common:

Reddish-orange discoloration of body fluids
Gastrointestinal upset (vomiting, diarrhea, anorexia)
Hepatotoxicity (elevated liver enzymes)
Skin rash
Fever

Serious / Severe:

Severe hepatotoxicity (jaundice, hepatic failure)
Thrombocytopenia
Hemolytic anemia
Renal failure (rare)
Anaphylaxis (rare)

Rare:

Pseudomembranous colitis
Exfoliative dermatitis
Stevens-Johnson syndrome
Interstitial nephritis
Lupus-like syndrome

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Macrolides (e.g., clarithromycin, azithromycin)	Synergistic activity against Rhodococcus equi; may increase risk of hepatotoxicity.	Moderate
Doxycycline	Synergistic activity against Brucella; no significant adverse interaction.	Mild
Corticosteroids	Rifampin increases metabolism of corticosteroids, reducing their efficacy.	Moderate
Ketoconazole/Itraconazole	Rifampin decreases azole concentrations; azoles may increase rifampin levels; monitor for toxicity.	High
Phenobarbital	Rifampin may increase phenobarbital metabolism, reducing its anticonvulsant effect.	Moderate
Warfarin	Rifampin increases warfarin metabolism, reducing anticoagulant effect; monitor coagulation.	High
Cyclosporine	Rifampin decreases cyclosporine levels, reducing immunosuppressive effect.	High
Fluoroquinolones (e.g., enrofloxacin)	May have additive or antagonistic effects depending on organism; generally avoid concurrent use for mycobacteria.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Nausea, vomiting, abdominal pain
Hepatotoxicity (elevated liver enzymes, jaundice)
CNS depression or agitation
Reddish-orange discoloration of skin and body fluids
Hypotension (with IV overdose)
Metabolic acidosis (rare)

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce vomiting if recent oral ingestion and animal is conscious. Administer activated charcoal to reduce absorption. Monitor liver function, renal function, and electrolytes. Provide IV fluids and supportive care. In severe cases, consider hemodialysis (though rifampin is highly protein-bound, dialysis may be limited). No specific antidote.

Food Animal Withdrawal Times

🥩 Meat: 10 days🥛 Milk: 7 days

Withdrawal times are not officially established in many countries for rifampin in food animals. The values provided are estimates based on pharmacokinetic data and should be used with caution. Extra-label use requires veterinary oversight and extended withdrawal periods may be necessary. Consult regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep container tightly closed. Oral suspension should be used within 4 weeks after reconstitution.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use in the US; used extra-label. Approved for human use.

Extra-Label (Off-Label) Use: In the US, extra-label use of rifampin in food animals is prohibited or restricted under AMDUCA because it is a human drug and may pose a public health risk (e.g., resistance). Use in food animals requires a valid veterinary-client-patient relationship and careful consideration of withdrawal times. In some countries, rifampin is not approved for veterinary use at all.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Rifampin is a valuable antibiotic for treating mycobacterial infections and certain intracellular pathogens in veterinary medicine. It is most commonly used in dogs and cats for tuberculosis, leprosy, and atypical mycobacterial infections, and in foals for Rhodococcus equi pneumonia. Due to rapid development of resistance, it must always be used in combination with other effective antibiotics. Key clinical considerations include: (1) monitoring for hepatotoxicity, especially with prolonged use; (2) informing owners about the harmless orange-red discoloration of body fluids; (3) being aware of significant drug interactions due to CYP450 enzyme induction; (4) ensuring accurate dosing, as bioavailability is reduced with food; and (5) in food animals, strict adherence to withdrawal times and regulatory restrictions. For mycobacterial infections, treatment may be required for months, and culture and sensitivity testing is recommended. In horses, rifampin is often combined with macrolides for R. equi pneumonia, but caution is advised due to potential gastrointestinal side effects. Overall, rifampin is a potent antibiotic that should be reserved for serious infections where other options are limited.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)